Molecular Docking , ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Canc J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Phys. 2008;77:311–319.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21(3):505–515.
   PubMed Web of Science ®Google Scholar
• Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol. 2001;11(5):339–352.
   Web of Science ®Google Scholar
• Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72(1):7–25.
   PubMed Web of Science ®Google Scholar
• Wang T, You Q, Huang FS, et al. Recent advances in selective estrogen receptor modulators for breast cancer. Mini Rev Med Chem. 2009;9(10):1191–1201.
   Web of Science ®Google Scholar
• Van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after treatment tamoxifen treatment of breast cancer. Lancet. 1994;343:448.
   PubMed Web of Science ®Google Scholar
• Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer- An overview and update. Mol Cell Endocrinol. 2015;418:220–234.
   PubMed Web of Science ®Google Scholar
• Kerru N, Gummidi L, Maddila S, et al. AReview on recent advances in nitrogen containing molecules and their biological applications. Molecules. 2020;25(8):1909.
   PubMed Web of Science ®Google Scholar
• Liu L, Tang Z, Chengze W, et al. Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents. Bioorg Med Chem Lett. 2018;28(6):1138–1142.
   Web of Science ®Google Scholar
• Leelananda SP, Lindert S. Computational methods in drug discovery. Beilstein J Org Chem. 2016;12:2694–2718.
   PubMed Web of Science ®Google Scholar
• Arrowsmith J. A decade of change. Nat Rev Drug Discov. 2012;11(1):17–18.
   PubMed Web of Science ®Google Scholar
• Hillisch A, Pineda LF, Hilgenfeld R. Utility of homology models in the drug discovery process. Drug Discov Today. 2004;9(15):659–669.
   PubMed Web of Science ®Google Scholar
• Ferreira RS, Glaucius O, Andricopulo AD. Integração das técnicas de triagem virtual e triagem biológica automatizada em alta escala: oportunidades e desafios em P&D de fármacos. Quim Nova. 2011;34(10):1770–1778.
   Google Scholar
• Yang Y, Qin J, Liu H. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors. J Chem Inform Model. 2011;51(3):680–692.
   PubMed Web of Science ®Google Scholar
• Omaima MA, Daabeesb HMG, Badawi WA. 2-Anilinopyrimidine derivatives: design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study. Bioorg Chem. 2020;99:103798.
   Web of Science ®Google Scholar
• Chang J, Ren H, Zhao M, et al. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. Eur J Med Chem. 2017;138:669–688.
   PubMed Web of Science ®Google Scholar
• Thomsen R, Christensen MH. MolDock: a new technique for high accuracy molecular docking. J Med Chem. 2006;49(11):3315–3321.
   PubMed Web of Science ®Google Scholar
• Bello Umar A, Uzairu A, Adamu Shallangwa G, et al. Computational evaluation of potent 2 (1Himidazol- 2-yl) pyridine derivatives as potential V600E-BRAF inhibitors. Egypt J Med Hum Genet. 2020;21(1):67. https://doi.org/10.1186/s43042-020-00111-2
   Google Scholar
• Sagiru Hamza A, Uzairu A, Ibrahim, et al., Tukur Ibrahim and Abdullahi Bello Umar. Chemo‑informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6‑diaryl‑2‑pyrimidinamine derivatives as anti‑cancer agents. Bull Natl Res Cent. 2021;45(1):167.
   Google Scholar
• Mohameda TK, Batrana RZ, Elseginyb SA, et al. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Bioorg Chem. 2019;85:253–273.
   Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.
   PubMed Web of Science ®Google Scholar
• Bickerton GR, Paolini GV, Besnard J, et al. Quantifying the chemical beauty of drugs. Nat Chem. 2012;4(2):90.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25.
   Web of Science ®Google Scholar
• Martin YC. A bioavailability score. J Med Chem. 2005;48(9):3164–3170.
   PubMed Web of Science ®Google Scholar
• Clark DE. In silico prediction of blood–brain barrier permeation. Drug Discov Today. 2003;8(20):927–933.
   PubMed Web of Science ®Google Scholar